S&P 500 Futures
(-0.04%) 5 476.50 points
Dow Jones Futures
(-0.07%) 38 791 points
Nasdaq Futures
(-0.01%) 19 920 points
Oil
(0.34%) $80.60
Gas
(1.22%) $2.82
Gold
(0.24%) $2 334.60
Silver
(-0.16%) $29.35
Platinum
(-0.15%) $969.40
USD/EUR
(0.01%) $0.932
USD/NOK
(-0.16%) $10.64
USD/GBP
(0.05%) $0.788
USD/RUB
(-1.87%) $86.80

Realaus laiko atnaujinimai Onconova Therapeutics Inc [ONTX]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta2 bal. 2024 @ 23:00

-0.47% $ 0.995

Live Chart Being Loaded With Signals

Commentary (2 bal. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by -0.99% compare to its pairs and should correct upwards.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...

Stats
Šios dienos apimtis 1.25M
Vidutinė apimtis 126 338
Rinkos kapitalizacija 20.90M
EPS $-0.240 ( Q1 | 2024-05-15 )
Kita pelno data ( $0 ) 2024-08-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.037
(Sector) 42.63
(Industry) 24.32
ATR14 $0.0140 (1.42%)
AADI -3.55%
ABCL -5.26%
ABCM 0.04%
ABEO -1.31%
ABIO -1.53%
ABOS -5.30%
ABSI -14.32%
ABUS -2.55%
ABVX -0.22%
ACAD -0.47%
ACER -17.95%
ACET -2.22%
ACGN 1.29%
ACHL 0.23%
ACHV 1.63%
ACIU -4.23%
ACLX -1.21%
ACRV -5.10%
ACST 0.62%
ACXP -0.42%
ADAG -5.64%
ADAP -7.23%
ADGI 0.87%
ADIL -2.29%
ADMA -1.79%
ADPT 0.32%
ADTX -7.69%
ADVM -3.94%
ADXN -6.11%
AEON 11.51%
AEZS -5.44%
AFMD -5.07%
AGEN -7.50%
AGIO -3.45%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW 53.45%
AKBA -1.87%
AKRO -4.46%
AKTX -6.33%
AKUS 0.00%
ALBO 0.00%
ALDX -1.34%
ALEC -2.35%
ALGS -5.76%
ALKS 2.08%
ALLK 0.86%
ALLO -2.13%
ALLR -3.01%
ALNA 3.16%
ALNY -1.93%
ALPN 0.00%
ALPX 0.00%
ALRN -0.31%
ALT -3.11%
ALVR -4.43%
ALXN 0.00%
ALXO -8.32%
ALZN -12.01%
AMRN -2.58%
AMTI -3.13%
ANAB -1.64%
ANEB -5.58%
ANGN 0.00%
ANIX -0.38%
ANL 0.61%
ANNX -4.63%
ANPC -3.15%
APGE -5.23%
APGN 8.48%
APGNW 30.65%
APLM -4.73%
APLS -3.98%
APLT -4.36%
APM 1.33%
APOP 0.38%
APRE 2.44%
APTO -3.96%
APTX 3.17%
APVO -20.53%
ARAV -13.39%
ARCT -9.26%
ARDS 20.48%
ARDX -0.94%
ARGX -2.25%
ARNA 0.00%
ARPO -0.90%
ARQT -7.76%
ARTL -0.38%
ARTLW 9.80%
ARVN -2.84%
ARWR -2.86%
ASLN -12.17%
ASMB -1.49%
ASND -2.39%
ATAI -2.19%
ATHA 2.36%
ATHE -1.61%
ATHX -33.50%
ATNF 15.09%
ATOS -4.17%
ATRA -16.93%
ATXI -1.66%
ATXS -3.50%
AUPH -1.95%
AURA 0.96%
AUTL -4.22%
AVBP -1.02%
AVEO 0.00%
AVIR -2.22%
AVRO 2.10%
AVTE -93.30%
AVTX 4.08%
AVXL -1.06%
AXLA 0.00%
AXSM 3.22%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -2.26%
BCAB -1.89%
BCDA -2.05%
BCDAW -33.33%
BCEL -1.32%
BCLI -8.47%
BCRX 1.13%
BCTX 4.96%
BCTXW 0.00%
BCYC -4.33%
BDRX 1.89%
BDTX -8.38%
BEAM -3.38%
BFRA -2.91%
BGNE -1.97%
BIOR -10.12%
BIVI 0.41%
BLCM -6.68%
BLI -5.88%
BLPH -0.79%
BLRX -3.79%
BLTE -0.72%
BLU 0.03%
BLUE -0.77%
BMEA -9.75%
BMRN 1.81%
BNOX 1.64%
BNTC 2.46%
BNTX -3.95%
BOLD -5.95%
BOLT -0.82%
BPMC -1.59%
BPTH 10.65%
BPTS -13.47%
BRNS -6.63%
BRTX 20.00%
BTAI -2.92%
BTTX -7.50%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI 6.06%
CABA -12.20%
CADL -0.96%
CALA 60.00%
CALC -1.62%
CALT 0.03%
CAPR -4.06%
CARA -27.26%
CARM -9.65%
CASI -8.04%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS 3.07%
CCCC -5.48%
CCXI 0.00%
CDAK 0.00%
CDIO -1.51%
CDIOW -23.08%
CDMO 5.72%
CDMOP 0.04%
CDT -6.11%
CDTTW -47.71%
CDTX -6.32%
CDXC -0.67%
CDXS -2.30%
CELC -2.79%
CELU -2.19%
CELUW -9.52%
CERC -1.68%
CERE -0.16%
CERO -7.87%
CEROW -44.78%
CFRX -27.95%
CGEM 0.74%
CGEN -5.31%
CGON -2.68%
CGTX 0.92%
CHMA -6.00%
CHRS -2.96%
CINC 0.00%
CING -1.09%
CINGW -48.24%
CKPT -4.25%
CLBS -16.75%
CLDX 0.69%
CLGN 1.19%
CLLS -4.89%
CLNN -2.48%
CLNNW -41.25%
CLRB -9.94%
CLSD -0.84%
CLSN -0.68%
CLVS 0.00%
CMMB -24.79%
CMND 1.83%
CMPI 0.00%
CMPX 5.41%
CMRA 0.40%
CMRAW 33.33%
CMRX 1.44%
CNCE 0.00%
CNSP 3.94%
CNST 0.00%
CNTA -6.39%
CNTB 3.13%
CNTX -1.02%
COCP -0.16%
COEPW -0.66%
COGT 4.45%
CORT -1.31%
COYA -6.11%
CPRX -0.40%
CRBP -11.76%
CRBU -2.23%
CRDF -1.11%
CRGX -4.78%
CRIS 1.11%
CRNX -1.37%
CRSP -2.79%
CRTX 2.63%
CRVO -1.89%
CRVS -5.39%
CSBR 1.19%
CTCX -8.04%
CTIC 0.06%
CTMX -0.72%
CTNM 0.00%
CTXR -1.50%
CUE -1.47%
CVAC -5.18%
CVKD 3.18%
CWBR -2.55%
CYAD -12.96%
CYCC -3.55%
CYCCP -1.79%
CYCN 6.00%
CYT -2.27%
CYTK -2.13%
CYTO 2.48%
DARE -3.31%
DAWN -4.60%
DBTX -0.81%
DBVT 1.01%
DFFN 10.28%
DICE 0.06%
DMAC -0.42%
DNLI -1.21%
DNTH -2.85%
DOMH 1.99%
DRMA 0.00%
DRMAW 0.00%
DRNA 0.00%
DRTS -1.32%
DRTSW 1.01%
DRUG 0.00%
DSGN 2.97%
DTIL -2.07%
DYAI -5.29%
EARS -1.77%
EDIT 0.20%
EDSA 1.04%
EFTR -3.13%
EFTRW -0.26%
EIGR 0.00%
ELAB 1.44%
ELDN -6.93%
ELEV -7.89%
ELOX -12.50%
ELTX -2.33%
ELVN -0.65%
ELYM -13.05%
ENGN -3.89%
ENGNW -7.06%
ENLV -3.47%
ENOB 1.79%
ENSC -0.55%
ENTA -6.00%
ENTO -2.80%
ENTX 0.00%
ENVB -4.64%
EPIX -8.75%
EPRX -0.19%
EPZM 0.00%
EQ 0.50%
EQRX -2.09%
EQRXW 0.00%
ERAS -7.83%
ERNA 2.60%
ERYP 1.30%
ESLA -6.38%
ESLAW -9.25%
ETNB 1.03%
ETON -5.90%
ETTX 0.00%
EVAX -19.54%
EVGN -2.14%
EVLO 50.00%
EWTX -0.80%
EXAI 1.19%
EXEL 0.18%
EYEG -0.43%
EYEN 1.57%
EYPT -3.94%
FATE -1.11%
FBIO 1.60%
FBIOP -1.05%
FBLG -5.34%
FBRX -7.46%
FDMT 0.72%
FENC 0.74%
FGEN -5.36%
FHTX 9.52%
FIXX 0.77%
FMTX 0.00%
FNCH -6.25%
FOLD -0.99%
FREQ 4.76%
FRLN 0.15%
FRTX -0.54%
FSTX 0.00%
FTRE 0.38%
FULC -6.04%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -4.58%
GANX 6.45%
GBIO 6.57%
GBT 0.01%
GDTC 2.16%
GERN -4.11%
GHRS 3.42%
GLMD -6.66%
GLPG 1.18%
GLSI 18.16%
GLTO -4.90%
GLUE -4.18%
GLYC -9.70%
GMAB -1.57%
GMDA 0.00%
GMTX 0.00%
GNCA -85.71%
GNFT 0.14%
GNLX 1.27%
GNPX 1.84%
GNTA -0.60%
GOSS 0.02%
GOVX -7.50%
GOVXW -24.72%
GPCR 0.85%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS -2.71%
GRTX -4.26%
GTHX -3.96%
GUTS -3.90%
GXGXW 41.67%
GYRE 4.44%
HALO 0.32%
HARP 0.09%
HCWB -9.73%
HEPA -6.36%
HGEN -84.62%
HILS 5.66%
HLVX 1.33%
HOOK -4.04%
HOTH -3.73%
HOWL 3.99%
HRMY 1.10%
HRTX -10.42%
HSTO 62.16%
HUMA -12.20%
HUMAW -5.97%
IBRX -2.18%
ICCC 2.84%
ICPT 0.21%
ICU 1.30%
ICUCW -10.39%
ICVX -0.91%
IDRA -23.04%
IDYA -1.44%
IFRX -3.21%
IGMS 0.41%
IKNA -0.57%
IKT 8.90%
IMAB -1.09%
IMCR -3.82%
IMGN 0.02%
IMGO 0.00%
IMMP -0.74%
IMMX -0.49%
IMNM -11.86%
IMNN -1.80%
IMPL -27.27%
IMRA 15.96%
IMRN -2.78%
IMRX 1.66%
IMTX -0.08%
IMTXW -2.70%
IMUX -4.20%
IMV 0.00%
IMVT 3.08%
INAB -8.26%
INBX -9.62%
INCY 0.93%
INDP 7.98%
INFI -52.38%
INKT -1.05%
INM -2.58%
INMB -2.47%
INO -1.65%
INSM 1.22%
INTS -5.63%
INVA 1.57%
INZY -2.95%
IOBT -6.11%
IONS 0.27%
IOVA -0.98%
IPA 0.48%
IPHA -10.64%
IPSC 0.64%
IRON -3.05%
ISEE 0.38%
ITOS -6.04%
ITRM -1.74%
IVA -10.10%
IVVD -6.96%
JAGX -6.67%
JANX -4.57%
JAZZ 1.43%
JNCE 0.00%
JSPR -2.80%
JSPRW 2.33%
JUNS 0.00%
JUNSW 0%
KA 4.11%
KALV -2.07%
KDNY 0.22%
KMPH -0.34%
KNSA -1.28%
KNTE -0.38%
KOD -4.27%
KPRX -21.08%
KPTI 1.69%
KRBP 4.17%
KRON -3.70%
KROS -9.68%
KRRO -16.54%
KRTX 0.03%
KRYS -0.04%
KTRA -2.35%
KTTA -2.85%
KTTAW 8.62%
KURA -0.62%
KYMR -4.42%
KYTX -17.21%
KZIA -1.29%
KZR -2.71%
LABP 0.57%
LBPH 1.67%
LBPS 0.00%
LBPSW 14.81%
LEGN -2.24%
LENZ -0.54%
LEXX -5.18%
LEXXW -9.42%
LGND 0.72%
LGNDV 0.00%
LGVN -24.76%
LIAN 0.00%
LIFE 2.70%
LIPO -1.23%
LIXT 0.40%
LIXTW 27.74%
LJPC -0.32%
LMNL 0.12%
LOGC 2.76%
LPCN 12.64%
LPTX -1.90%
LQDA 3.01%
LRMR -14.91%
LSTA -4.97%
LTRN -8.57%
LUMO -2.95%
LVTX -9.52%
LXEO -6.50%
LXRX -5.49%
LYEL -8.05%
LYRA -8.37%
MACK 0.00%
MBIO 476.92%
MBRX -4.83%
MCRB -5.28%
MDGL -0.31%
MDNA -13.16%
MDWD 1.00%
MDXG 0.59%
MEIP 1.41%
MESO -0.55%
MGNX -4.03%
MGTA -7.74%
MGTX -2.23%
MGX -24.14%
MIRM 27.31%
MIRO 0.59%
MIST -1.42%
MITO 0.00%
MLEC -4.55%
MLECW 9.20%
MLND -5.36%
MLTX -2.99%
MLYS -3.02%
MNKD -1.04%
MNMD -3.36%
MNOV 0.00%
MNPR -8.51%
MOLN 8.81%
MOR 0.88%
MORF -1.25%
MREO 0.00%
MRKR 16.59%
MRNA -1.52%
MRNS -1.02%
MRSN -1.45%
MRTX -0.17%
MRUS -1.38%
MRVI -3.99%
MTCR -1.29%
MTEM 1.54%
MTP -18.50%
MURA 2.17%
MYMD 4.19%
NAMS -7.03%
NAMSW -7.61%
NAUT 0.00%
NBRV 0.71%
NBSE -1.56%
NBTX 4.77%
NCNA -1.64%
NERV 8.96%
NEXI 0.00%
NGM -1.28%
NGNE -6.08%
NKGN -4.44%
NKGNW 39.76%
NKTR 0.00%
NKTX -5.66%
NLSP 30.09%
NLSPW -16.67%
NMRA -4.09%
NMTR -42.97%
NOVN -24.84%
NRBO 0.45%
NRIX 0.72%
NRSN -3.82%
NRSNW 6.50%
NRXP 0.99%
NRXPW -15.65%
NRXS -6.06%
NTBL 13.82%
NTEC -12.45%
NTHI 0%
NTLA 0.08%
NTRBW -6.25%
NUVL -0.77%
NVAX -2.43%
NVCT 1.18%
NVIV -34.28%
NXTC -10.63%
NYMX -0.05%
OABI 0.95%
OABIW 13.46%
OBIO 0.88%
OBSV 0.00%
OCEA 10.64%
OCGN -5.63%
OCS -1.09%
OCUL -4.35%
OCUP 1.82%
ODT -4.27%
OKYO 0.00%
OLMA -3.96%
OMER -0.49%
OMGA -8.37%
ONCO 12.54%
ONCR -3.08%
ONCS 31.87%
ONCT -0.12%
ONCY -0.98%
ONTX -0.47%
ONVO 0.62%
OPNT 0.00%
OPT -5.51%
ORGS -1.72%
ORIC -0.67%
ORMP -0.44%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -1.43%
OVID -76.00%
OYST 0.00%
PALI 0.86%
PASG -3.81%
PBLA 9.76%
PBM -0.02%
PBYI 2.89%
PCSA 5.71%
PCVX -1.45%
PDSB -4.13%
PEPG 0.70%
PGEN 0.00%
PHAR 2.17%
PHAS 0.00%
PHAT 3.08%
PHIO 4.14%
PHIOW 36.47%
PHVS -0.53%
PHXM -5.20%
PIRS -5.64%
PKBO 0.00%
PKBOW 999 900.00%
PLRX -5.08%
PLUR 0.00%
PMN -5.59%
PMVP -1.20%
PNT 0.16%
PPBT -11.48%
PRAX -6.21%
PRDS 0.93%
PRLD 0.77%
PROG -3.47%
PROK 6.96%
PRQR -3.41%
PRTA -0.20%
PRTC -0.72%
PRTG -1.96%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV 0.00%
PSTX 1.81%
PTCT -1.14%
PTE -0.82%
PTGX -2.76%
PTIXW 2.50%
PULM 3.72%
PXMD -1.92%
PYPD -0.36%
PYXS -3.43%
QLGN -11.72%
QNCX 0.00%
QNRX -10.97%
QSI -2.92%
QSIAW 0.00%
QTTB 3.82%
QURE -4.09%
RAIN -1.63%
RANI -5.46%
RAPT -0.30%
RARE 1.92%
RCKT -3.02%
REGN 0.85%
RENB -3.05%
REPL -6.63%
RETA 0.02%
REUN -0.89%
REVB 1.36%
REVBU 3.46%
REVBW 25.20%
RGLS -1.66%
RGNX -6.20%
RIGL -2.79%
RLAY -3.01%
RLMD -0.33%
RLYB -6.15%
RNA -0.10%
RNAC -14.55%
RNAZ -5.83%
RNXT 14.41%
ROIV 0.28%
ROIVW 4.56%
RPHM -0.60%
RPRX -1.15%
RPTX 0.00%
RUBY 2.70%
RVLP -32.05%
RVMD -3.94%
RVMDW -23.93%
RVNC -0.71%
RVPH -0.68%
RVPHW 11.54%
RXDX 0.09%
RXRX 1.19%
RYTM -3.76%
RYZB 0.02%
RZLT -2.53%
SABS 3.17%
SABSW -32.14%
SAGE -6.08%
SANA -1.32%
SAVA 0.81%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI 60.46%
SCPH -1.69%
SCPS 0.00%
SEEL -4.62%
SEER -3.37%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO -17.30%
SGMT 1.93%
SGTX -2.56%
SIOX 22.63%
SLDB -5.44%
SLGL -2.22%
SLN -1.55%
SLNO 0.19%
SLRX 2.89%
SLS -16.67%
SMMT -5.84%
SNDX -1.14%
SNGX -5.91%
SNPX -3.97%
SONN -4.75%
SPPI -0.49%
SPRB 0.49%
SPRC -3.16%
SPRO -5.88%
SRNE 20.00%
SRPT -4.89%
SRRA 0.00%
SRRK -7.09%
SRZN -1.70%
STAB 0.00%
STOK -4.00%
STRO -7.51%
STSA 0.00%
STTK -19.55%
SURF -0.93%
SVRA -5.15%
SWTX -4.88%
SYBX -0.63%
SYRS -4.83%
TALS -0.73%
TARA -0.78%
TARS -6.91%
TBPH -0.59%
TCBP -8.64%
TCDA 0.00%
TCON 6.35%
TCRR 0.00%
TCRT 1.05%
TCRX -11.43%
TECH -1.40%
TENX -3.43%
TERN -2.93%
TFFP 0.52%
TGTX 0.12%
THRX 0.12%
TIL -2.06%
TLC 0.00%
TLSA 5.78%
TNGX 5.04%
TNXP -2.61%
TNYA -1.79%
TPST 0.34%
TRDA -3.61%
TRVI 2.08%
TRVN -1.88%
TSHA 1.51%
TSVT 3.29%
TTNP 1.45%
TVTX 2.23%
TYRA -8.69%
UBX -4.17%
UNCY 0.22%
URGN -4.79%
UTHR 3.12%
VACC 11.36%
VALN -1.55%
VAXX -0.11%
VBIV -3.61%
VBLT -8.77%
VCEL -1.37%
VCNX -3.70%
VCYT 1.96%
VERA -0.83%
VERU 2.29%
VERV -2.77%
VIGL -2.08%
VINC -4.90%
VIR -5.85%
VIRI 4.95%
VIRX -3.62%
VKTX 0.00%
VLON -13.04%
VNDA 1.76%
VOR 1.74%
VRCA 0.49%
VRDN -1.93%
VRNA 10.04%
VRPX 10.77%
VRTX -1.46%
VSTM 0.00%
VTGN -2.84%
VTVT -0.10%
VTYX -4.51%
VXRT -8.25%
VYGR -2.94%
VYNE 2.16%
VYNT 7.78%
WINT 7.98%
WVE -3.85%
XBIO 6.75%
XBIT -0.33%
XCUR -3.10%
XENE -1.75%
XERS -0.91%
XFOR -2.75%
XLO -6.86%
XLRN 0.00%
XNCR -5.15%
XOMA -4.31%
XOMAO 0.68%
XOMAP -0.14%
XRTX 1.96%
YMAB -1.34%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 1.55%
ZNTL -5.09%
ZSAN 0.00%
Insider Trading
Date Person Action Amount type
2024-03-13 Guerin Mark Patrick Buy 8 666 Common Stock
2024-03-14 Guerin Mark Patrick Sell 2 591 Common Stock
2024-03-13 Guerin Mark Patrick Sell 8 666 Restricted Stock Units
2024-03-13 Fruchtman Steven M Buy 23 111 Common Stock
2024-03-14 Fruchtman Steven M Sell 8 727 Common Stock
INSIDER POWER
74.56
Last 95 transactions
Buy: 2 889 396 | Sell: 191 603
Koreliacija (AI algo v.1.1b): Undervalued: -0.99% $0.975 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.03 (neutral)
Trumpas: 0.45 (neutral)
Signal:(62.373) Neutral

Onconova Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Onconova Therapeutics Inc Koreliacija - Valiuta/Žaliavos

The country flag -0.48
( neutral )
The country flag -0.58
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.20
( neutral )
The country flag -0.15
( neutral )
The country flag 0.27
( neutral )

Onconova Therapeutics Inc Finansinės ataskaitos

Annual 2023
Pajamos: $226 000
Bruto pelnas: $226.00B (100 000 000.00 %)
EPS: $-0.900
FY 2023
Pajamos: $226 000
Bruto pelnas: $226.00B (100 000 000.00 %)
EPS: $-0.900
FY 2022
Pajamos: $226 000
Bruto pelnas: $212 000 (93.81 %)
EPS: $-0.880
FY 2021
Pajamos: $226 000
Bruto pelnas: $0.00 (0.00 %)
EPS: $-0.960

Financial Reports:

No articles found.

Onconova Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Onconova Therapeutics Inc

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.

Total Execution Time: 1.1362500190735 seconds
Number of API calls: 3
Number of DB calls: 9